Sponsored by
Patients in the TTFields group had median time to intracranial progression of 21.9 months versus 11.3 months for the control group. While this result is positive, preliminary analyses of secondary endpoints (time to neurocognitive failure, overall survival, and radiologic response rate) did not demonstrate statistical significance. Analysis of additional secondary endpoints (quality of life and time to distant progression) are ongoing and will be shared in a future publication.